CBS 2019
CBSMD教育中心
中 文

科学研究

Abstract

Recommended Article

Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes Clinical impact of conduction disturbances in transcatheter aortic valve replacement recipients: a systematic review and meta-analysis Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial Noninvasive Imaging for the Evaluation of Diastolic Function: Promises Fulfilled 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT Proteomics to Improve Phenotyping in Obese Patients with Heart Failure with Preserved Ejection Fraction Long-Term Outcomes After PCI or CABG for Left Main Coronary Artery Disease According to Lesion Location

Review ArticleVolume 74, Issue 12, September 2019

JOURNAL:J Am Coll Cardiol. Article Link

From Early Pharmacology to Recent Pharmacology Interventions in Acute Coronary Syndromes

Szummer K, Jernberg T, Wallentin L. Keywords: ACS; antithrombotic treatment; clinical trials; MI; Non STEM; outcomes; PCI; reperfusion treatment; revascularization; STEMI

ABSTRACT


This focus seminar will take the reader through the history and pivotal trials that have formed the current state-of-the-art management for acute coronary syndromes. The identification of a ruptured plaque with thrombus formation and subsequent occlusion or downstream embolization in the coronary artery was the key to developing new and effective treatment strategies. The traditional wait-and-see approach with prolonged bedrest was replaced in the 1980s by immediate pharmacological reperfusion of the occluded coronary artery and long-term aspirin to prevent reinfarction. Mechanical reperfusion with percutaneous coronary intervention with stenting and more intense platelet inhibition with P2Y12 inhibitors further improved outcomes from early 2000s. Adjunctive treatment regimens, including anticoagulants, statins, and neurohormonal inhibition, were found to further reduce mortality and prevent new infarctions. Taken together, the use of new combined pharmacological and interventional treatment strategies has led to a remarkable decrease in 1-year mortality from around 22% in 1995 to around 11% by 2014.